EGAPP|Evaluation of Genomic Applications in Practice and Prevention|Home

helix Evaluation of Genomic Applications in Practice and Prevention (EGAPP) is an initiative launched in 2004 to support a coordinated, systematic process for evaluating genetic tests and other genomic applications that are in transition from research to clinical and public health practice in the United States.

The EGAPP Working Group was established in 2005 to support the development of a systematic process for assessing the available evidence regarding the validity and utility of rapidly emerging genetic tests for clinical practice. This independent, multidisciplinary panel prioritizes and selects tests, reviews CDC-commissioned evidence reports and other contextual factors, highlights critical knowledge gaps, and provides guidance on appropriate use of genetic tests in specific clinical scenarios.

EGAPP Initiative announces five new EGAPP Working Group members
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative announces the selection of five new members who will join the EGAPP Working Group. Two current members complete their terms this year. Read more.

EGAPP Working Group Releases First Recommendation Statement on Genetic Testing. The recommendation statement appears in the December issue of Genetics in Medicine.

See the Working Group announcement.
Read the Genetics in Medicine press release.

Recommendations

Testing for Cytochrome P450 Polymorphisms (CYP450) in Adults with Non-Psychotic Depression Prior to Treatment with Selective Serotonin Reuptake Inhibitors (SSRIs)

Evidence Reports

Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes
The Johns Hopkins University Evidence Based Practice Center | January 2008

Hereditary Nonpolyposis Colorectal Cancer: Diagnostic Strategies and Their Implications
Tufts New England Medical Center Evidence Based Practice Center | May 2007

Testing for Cytochrome P450 Polymorphisms (CYP450) in Adults with Non-Psychotic Depression Prior to Treatment with Selective Serotonin Reuptake Inhibitors (SSRIs)
Duke University AHRQ Evidence-based Practice Center | January 2007

Meetings

Working Group Meeting, September 30 – October 1, 2008
Talaris Conference Center ~ Seattle, WA
Announcement | Agenda

The EGAPP initiative is sponsored by CDC's National Office of Public Health Genomics; however, the views
expressed on this website do not necessarily represent the views of the funding agency, CDC.